Overview

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This trial aims to study the efficacy and safety of cannabidivarin (CBDV) as a treatment for children with PWS.
Phase:
Phase 2
Details
Lead Sponsor:
Montefiore Medical Center
Collaborators:
Foundation for Prader-Willi Research
GW Pharmaceuticals Ltd.